Phenylketonuria Clinical Trial
Official title:
The Effects of an Acute Bout of Moderate Intensity Exercise on Plasma Amino Acids in Subjects With Phenylketonuria
Phenylketonuria (PKU), an inherited genetic disorder, can cause irreversible brain damage,
declined executive function, and autistic tendencies unless a phenylalanine (Phe) restricted
diet is consistently maintained throughout life. Promoting anabolism, the uptake of free
amino acids from the extracellular space, is a key component to maintaining plasma
phenylalanine concentrations within treatment range among patients with PKU. Exercise
promotes muscle protein synthesis and anabolism, but the effect on blood phenylalanine
concentrations in patients with PKU has not been reported.
Our objective is to assess the impact of an acute bout of moderate intensity exercise on
protein oxidation and plasma amino acid concentrations, as a potential adjunctive therapy
for patients with PKU.
The investigators hypothesize that moderate intensity exercise decreases amino acid
oxidation, increases muscle protein synthesis, and promotes tissue uptake of essential amino
acids, thereby lowering plasma phenylalanine concentrations in patients with
Phenylketonuria.
The indicator amino acid oxidation technique utilizes a carbon labeled isotope (L-[13C])
tracer that is ingested orally and is measured in expired breath. This method is based on
the theory that if one essential amino acid is deficient, all other amino acids will be
oxidized until a break-point is reached and at that time all amino acids will be
incorporated into muscle protein synthesis. Using a randomized crossover design the
investigators plan to investigate the effects of an acute bout of moderate intensity
treadmill exercise versus sedentary activities on plasma amino acids in four subjects with
PKU. The long-term goal of this novel research is to determine if exercise could be used as
an adjunctive therapy to improve the management of plasma phenylalanine levels and promote a
normal, healthy quality of life among patients with PKU.
Patient Recruitment: Four post-pubertal participants ranging from 14-17 years of age with
classical phenylketonuria (PKU), treated at Oregon Health & Science University, will
participate in this pilot study. Participants will be recruited during their routine clinic
visit at Doernbecher Children's Hospital Metabolic clinic.
Study Design: This randomized crossover clinical trial will compare the effects of moderate
intensity exercise and sedentary activities on amino acid oxidation and plasma amino acid
pools using the indicator amino acid oxidation technique. Each participant will be studied
on two separate occasions over a one-month period.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05099640 -
A Study of PTC923 in Participants With Phenylketonuria
|
Phase 3 | |
Completed |
NCT01924026 -
Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study
|
N/A | |
Completed |
NCT01428258 -
Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria
|
N/A | |
Completed |
NCT00925054 -
Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU
|
Phase 2 | |
Completed |
NCT00778206 -
PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
|
||
Recruiting |
NCT05948020 -
Efficacy and Safety of Orally Administered Engineered Probiotics (CBT102-A) for the Treatment of Children With Phenylketonuria
|
N/A | |
Recruiting |
NCT05781399 -
First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
|
Phase 1 | |
Completed |
NCT02555579 -
Simplified Diet Approach in Phenylketonuria
|
N/A | |
Completed |
NCT03097250 -
MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria
|
||
Completed |
NCT01965691 -
Protein Requirements in Children With Phenylketonuria (PKU)
|
N/A | |
Completed |
NCT01965912 -
Kuvan®'s Effect on the Cognition of Children With Phenylketonuria
|
Phase 4 | |
Completed |
NCT00789568 -
A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT00688844 -
Nutritional and Neurotransmitter Changes in PKU Subjects on BH4
|
N/A | |
Terminated |
NCT01465100 -
Liver Cell Transplant for Phenylketonuria
|
Phase 1/Phase 2 | |
Completed |
NCT01732471 -
Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria
|
Phase 3 | |
Completed |
NCT04879277 -
Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria
|
N/A | |
Completed |
NCT02176603 -
Observational Study of Endothelial Dysfunction in Phenylketonuria
|
N/A | |
Completed |
NCT01869972 -
Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia
|
N/A | |
Completed |
NCT01819727 -
An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165
|
Phase 3 | |
Completed |
NCT01560286 -
A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
|
Phase 2 |